Chronic Myelogenous Leukemia: Initiating, Switching, and Monitoring Therapy

The introduction of targeted therapy over the past decade has transformed the outlook for patients with chronic myelogenous leukemia (CML). Imatinib as front-line therapy in patients with chronic phase CML has shown excellent results at 7 years in the IRIS trial. However, patients need to be closely monitored for molecular and cytogenetic responses at specific time points. Assessment of response milestones is important for identifying patients who fit the criteria for suboptimal response or failure to imatinib. For these patients, dose optimization or switching to a newer tyrosine kinase inhibitor (TKI) should be considered. Patients who are intolerant to imatinib despite adequate management of adverse events may also benefit from the newer TKIs. This educational activity will utilize a case-based approach to address scenarios that are commonly encountered by clinicians who treat patients with CML, from initiating treatment, to monitoring response, to switching therapy when necessary.

Available until October 30, 2010, this activity offers:
Physicians: 1.5 AMA PRA Category 1 Credits^™
Nurses: 1.5 contact hours

Program Agenda:

• Program Introduction – 2 minutes
• Presentation by Dr. Cortes – 43 minutes
• Presentation by Dr. Radich – 42 minutes
• Evaluation Completion – 5 minutes

This activity is jointly sponsored by SCEPTER^™ and Quintiles Medical Education. This activity is co-provided by Global Education Group and SCEPTER^™.